0.52 | 3.64%
| Price and Volume | |
|---|---|
| Recent Price | 14.30 |
| 52 Week High | 15.27 |
| 52 Week Low | 8.58 |
| Avg. Daily Vol. (Mil) | 2.70 |
| Beta (3 year) | 1.52 |
| Share Related Items | |
| Mkt Cap (Mil) | 8,427.65 |
| Shares Out (Mil) | 589.35 |
| Float (Mil) | 0.00 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.50 |
| Current Ratio | 3.30 |
| LT Debt/ Equity | 0.76 |
| Total Debt / Equity | 0.76 |
| Valuation Ratios | |
| Price Earnings | 22.30 |
| Price/Sales | 9.37 |
| Price/Book | 10.43 |
| Price/Cash Flow | 18.70 |
| Per Share Data | |
| Earnings | 0.64 |
| Sales | 1.53 |
| Book Value | 1.37 |
| Cash Flow | 0.77 |
| Business Summary | |
|---|---|
| Elan Corporation, PLC is a neuroscience-based biotechnology company, which operates its business in two areas BioNeurology and EDT. | |
| General Information | |
| Lincoln House, Lincoln Place
Lower Grand Canal Street Dublin, 2 |
|
| 9.9951596528126E-9 | |
| www.elan.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 412 | |
| CEO: G. Kelly Martin | |
| Short Interest | |
| Current Month (Mil) | 8.52 |
| Previous Month (Mil) | 8.55 |
| Short Interest Ratio (Days) | 3.30 |
| Management Effectiveness | |
| Return on Equity | 47.80 |
| Return on Assets | 22.20 |
| Return on Investments | 27.10 |
| Profitability | |
| Gross Margin | 51.70 |
| EBIT Margin | 50.10 |
| Profit Margin | 42.90 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,580.69 | 1,332.42 | 2,870.99 | 17.31 |
Oil *
106.79
|
|
UP
125.86 |
UP
14.60 |
UP
33.46 |
DOWN
0.14 |
10 Yr
1.73%
SPDR Gold
151.02
|
|
+1.01%
|
+1.11%
|
+1.18%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet